News
The Catalan Institute of Oncology and IDIBELL lead the PIECES Project aimed at implementing interventions in the field of cancer prevention
Funded by the European Union, the project aims to develop, evaluate and disseminate a methodological implementation framework for cancer known as the ‘Integrated Implementation Kit’ in six risk factors, such as tobacco, alcohol, ‘sun exposure, the human papilloma virus, nutrition and physical activity.
A new endoscopy study from Bellvitge published in the main scientific journal of the digestive specialty
The American Journal of Gastrointestinal Endoscopy published a multicenter study on the treatment of gastrointestinal subepithelial tumors led by the Bellvitge Biomedical Research Institute (IDIBELL) and the Digestive Endoscopy Unit of the Bellvitge University Hospital (HUB).
Small RNAs in semen are useful biomarkers to determine the origin of azoospermia
The objective was to select non-invasive biomarkers with diagnostic and prognostic utility, which allow the identification of individuals with a real possibility of recovering sperm from a testicular biopsy, necessary for assisted reproduction treatment.
The omic sciences to advance in precision medicine are the focus of the NeuroDebate 2023 conference
This past June 9 and 10, NeuroDebate took place, a conference promoted by the Bellvitge University Hospital (HUB), the Bellvitge Biomedical Research Institute (IDIBELL) and the University of Barcelona.
A new study seeks solutions to minimize complications in heart transplants
The Bioheart group has carried out a retrospective analysis of 2,376 heart transplants performed in 14 hospitals throughout the country and has concluded that the choice between peripheral or central cannulation for ECMO-Venoarterial placement determines an improvement in survival.
A new paradigm in the treatment of patients with diffuse large B-cell lymphoma, one of the most aggressive blood cancers
It is the first treatment in the last 30 years that represents a relative improvement of 38% in the overall survival of patients compared to standard treatment. The results of Phase III study ZUMA-7 show that this new treatment with Yescarta (axicabtagén ciloleucel, known as axicel) reduces the risk of death by 27.4%.
Depolymerization of microtubules contributes to spontaneous neurotransmitter release
A study that reveals that microtubules, apart from their known structural role in cells, they also exert an active influence on neuronal communication.
Advances in the approach to multiple sclerosis, within reach of patients on World MS Day
The Neurological Diseases and Neurogenetics research group of the Bellvitge Biomedical Research Institute (IDIBELL) and the Multiple Sclerosis Unit of the Neurology Service of the HUB have co-organized this day to explain the new advances achieved in the approach and search of the disease and to give voice to patients.
IDIBELL and the University of Iowa developed a new molecule for targeted treatment against cancer
It is an aptamer, a small nucleic acid molecule that specifically recognizes a receptor highly expressed in tumor cells of breast cancer, sarcoma, melanoma, and colon cancer, among others. The new molecule could be linked to cancer treatments and used as a platform for localized drug delivery that reduces side effects.